A First-in-Human, Open-Label, Dose Escalation and Expansion Study of Orally Administered NX-019 in Patients with Advanced, EGFR Mutant Cancer
The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with Advanced,
EGFR Mutant Cancer for a study. The purpose of this study is to learn about the safety, tolerance and effectiveness of the study drug, NX-019, at different doses to see what effects (good and bad) it has on you and your cancer. In this study, different doses of NX-019 will be given to study subjects to determine the recommended dose for treating your cancer safely.